Frontlight ResearchEarly access
Myeloproliferative neoplasms trials, also abroad
239 open Myeloproliferative neoplasms trials worldwide. Travel and costs are your own unless the study pays them; ask the study team first.
The same trial often runs in several countries
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib has 7 sites in Croatia and runs in 19 countries. If a site near you is full, another one may still take people.
See Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib in all 19 countries